Incyte | INCY - Sales Revenues

Stock Price
100.52
Daily Change
0.43 0.43%
Monthly
-2.85%
Yearly
37.36%
Q1 Forecast
98.18

Incyte reported $1.51B in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 284M 5.4M Dec/2025
Agenus USD 24.07M 2.77M Mar/2025
Agios Pharmaceuticals USD 19.97M 7.07M Dec/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
Amgen USD 9.9B 340M Dec/2025
BioCryst Pharmaceuticals USD -86.95M 204.03M Dec/2024
Biogen USD 2.28B 250M Dec/2025
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Exelixis USD 598.66M 860K Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
Incyte USD 1.51B 140M Dec/2025
Ionis Pharmaceuticals USD 203M 46M Dec/2025
MacroGenics USD 72.84M 50.6M Sep/2025
Merck USD 16.4B 880M Dec/2025
Moderna USD 678M 342M Dec/2025
Nektar Therapeutics USD 24.12M 635K Sep/2024
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Novartis USD 13.91B 144M Sep/2025
Novartis USD 14.36B 478M Sep/2025
Pfizer USD 17.58B 880M Dec/2025
PTC Therapeutics USD 164.7M 46.3M Dec/2025
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025